Lecalpin (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in vascular smooth muscle. This inhibition prevents calcium influx, leading to vasodilation, reduced peripheral resistance, and a subsequent fall in systemic blood pressure. Its high lipophilicity provides a prolonged antihypertensive effect.

The appropriate dose of Lecalpin is determined by the prescribing healthcare professional based on the individual’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lecalpin belongs to the dihydropyridine calcium‑channel blocker class, offering potent vasodilation with a relatively low incidence of reflex tachycardia compared with older agents. Compared with ACE inhibitors or ARBs, it provides an alternative mechanism, useful when those classes are contraindicated or not tolerated.

Lecalpin should be stored at room temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lecalpin is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, though rare, include severe hypotension, myocardial infarction, hepatic dysfunction, allergic reactions such as rash or angioedema, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience chest pain, fainting, rapid weight gain, or signs of an allergic reaction.

Lecalpin is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. It should be used with caution in individuals with severe hepatic impairment, unstable angina, or those taking strong CYP3A4 inhibitors. A healthcare professional must evaluate suitability before prescribing.